Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab

To find prognostic factors for advanced ovarian cancer patients undergoing first-line therapy with carboplatin, paclitaxel and bevacizumab, we investigated the expression of a disintegrin and metalloprotease 17 (ADAM17) in cancer tissues. ADAM17 has been involved in ovarian cancer development, progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabbi, Marina, Costa, Delfina, Russo, Daniela, Arenare, Laura, Gaggero, Gabriele, Signoriello, Simona, Scambia, Giovanni, Pisano, Carmela, Colombo, Nicoletta, Losito, Nunzia Simona, Filaci, Gilberto, Spina, Anna, Califano, Daniela, Scognamiglio, Giosuè, Gadducci, Angiolo, Mezzanzanica, Delia, Bagnoli, Marina, Ferrini, Silvano, Canzonieri, Vincenzo, Chiodini, Paolo, Perrone, Francesco, Pignata, Sandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498026/
https://www.ncbi.nlm.nih.gov/pubmed/36140519
http://dx.doi.org/10.3390/diagnostics12092118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498026/
https://www.ncbi.nlm.nih.gov/pubmed/36140519
http://dx.doi.org/10.3390/diagnostics12092118

Ejemplares similares